Login to Your Account

$100M Up Front for U.S. Daxas Rights

Nycomed Deal Gets Forest New Shot at COPD Market

By Jennifer Boggs

Tuesday, August 11, 2009
Five months after a regulatory snag pointed to a delay with a partnered chronic obstructive pulmonary disease drug, Forest Laboratories Inc. picked up another drug that could offer near-term entry into the multibillion-dollar COPD market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription